Sandbox:Qurrat: Difference between revisions
Jump to navigation
Jump to search
(→tab) |
(→tab) |
||
Line 10: | Line 10: | ||
| colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Clinical manifestations</small>''' | | colspan="7" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Clinical manifestations</small>''' | ||
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Para-clinical findings</small> | ! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Para-clinical findings</small> | ||
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Gold standard</small>''' | | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Gold standard</small>''' | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Additional findings</small> | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Additional findings</small> | ||
Line 16: | Line 15: | ||
| colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Symptoms</small>''' | | colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''<small>Symptoms</small>''' | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Physical examination</small> | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Physical examination</small> | ||
|- | |- | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Lab Findings</small> | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |<small>Lab Findings</small> | ||
Line 67: | Line 65: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterine sarcoma|<small>Uterine</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterine sarcoma|<small>Uterine</small>]] | ||
Line 86: | Line 84: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphoma|<small>Uterine</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphoma|<small>Uterine</small>]] | ||
Line 105: | Line 103: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Uterine</small> <small>[[leiomyoma]]</small> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Uterine</small> <small>[[leiomyoma]]</small> | ||
Line 123: | Line 121: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Malignant</small> <small>mixed</small> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>Malignant</small> <small>mixed</small> | ||
Line 149: | Line 147: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Cervical cancer|Cervical]]</small> <small>[[Cervical cancer|cancer]]</small> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Cervical cancer|Cervical]]</small> <small>[[Cervical cancer|cancer]]</small> | ||
Line 173: | Line 171: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Metastasis]]</small> <small>to the uterus</small> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Metastasis]]</small> <small>to the uterus</small> | ||
Line 195: | Line 193: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial polyp|<small>Endometrial</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial polyp|<small>Endometrial</small>]] | ||
Line 214: | Line 212: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial hyperplasia|<small>Endometrial</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Endometrial hyperplasia|<small>Endometrial</small>]] | ||
Line 233: | Line 231: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Fetus]]</small> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |<small>[[Fetus]]</small> | ||
Line 251: | Line 249: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adenomyoma|<small>Uterine</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adenomyoma|<small>Uterine</small>]] | ||
Line 271: | Line 269: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematometra|<small>Hematometra</small>]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematometra|<small>Hematometra</small>]] | ||
Line 289: | Line 287: | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
|- | |- | ||
| | | |
Revision as of 18:49, 29 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
tab
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||
Vaginal
bleeding |
Pelvic
pain |
pelvic
pressures |
Abdominal
distentions |
Pelvic
mass |
Abdominal
distension |
Physical exam 3 | Hb | CEA-19 | Pelvic
examination |
Pelvic
ultrasound |
MRI | |||||
Uterine cancer | ||||||||||||||||
Uterine | ||||||||||||||||
Uterine | ||||||||||||||||
Uterine leiomyoma | ||||||||||||||||
Malignant mixed
Mullerian tumour (MMMT) of the uterus |
||||||||||||||||
Cervical cancer
with uterine invasion |
||||||||||||||||
Metastasis to the uterus
from a non gynaecologcial malignancy |
||||||||||||||||
Endometrial | ||||||||||||||||
Endometrial | ||||||||||||||||
Fetus | ||||||||||||||||
Uterine | ||||||||||||||||
Hematometra | ||||||||||||||||
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||
Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | ||||
Uterine cancer | |||||||||||||||
Uterine sarcoma | |||||||||||||||
Infection | |||||||||||||||
Diseases | Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | Histopathology | Gold standard | Additional findings |
Abscess | |||||||||||||||
Septic emboli | |||||||||||||||
Fungi | |||||||||||||||
Differential Diagnosis 1 | |||||||||||||||
Differential Diagnosis 2 | |||||||||||||||
Differential Diagnosis 3 | |||||||||||||||
Diseases | Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | Histopathology | Gold standard | Additional findings |
Differential Diagnosis 4 | |||||||||||||||
Differential Diagnosis 5 | |||||||||||||||
Differential Diagnosis 6 |
Table for Differential Diagnosis of Small Intestine Cancer
ABBREVIATIONS:
N/A: Not available, NL: Normal,